rhASM
Phase 1Small molecule
SanofirhASM is one of 7 small molecule programs targeting Niemann-Pick disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Niemann-Pick Disease
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Busulfex
Akero TherapeuticsApproved
N-Acetyl Cyteien
SStanford University
Phase 2
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
IB1001
MMedexus Pharma, Inc.
Phase 2
VTS-270
VVtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Phase 2
rhASM
SanofiPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhASM. EMBL-EBI & Wellcome Sanger Institute.
- [4]